Boston University Charles River Campus
bu.eduTotal trials
137
Active
32
Phase 3
3
Total enrollment
16,589
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sertraline | — | — | — | — | — | 1 |
Next readouts
- 2027-04-01
Top conditions
- Stroke7
- Parkinson Disease7
- Anxiety Disorders7
- Anxiety6
- Depression6
- Knee Osteoarthritis5
- Autism Spectrum Disorder4
- Schizophrenia4
Frequently asked questions about Boston University Charles River Campus
- How many clinical trials does Boston University Charles River Campus have on ClinicalTrials.gov?
- Boston University Charles River Campus is listed as the lead sponsor on 137 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Boston University Charles River Campus's trials are in Phase 3?
- 3 of Boston University Charles River Campus's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Boston University Charles River Campus focus on?
- Boston University Charles River Campus's most-studied conditions on ClinicalTrials.gov are Stroke, Parkinson Disease, Anxiety Disorders, Anxiety, Depression.
- When are Boston University Charles River Campus's next clinical trial readouts?
- Boston University Charles River Campus has 1 upcoming primary-completion readout tracked here; the soonest is “Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety”, expected around 2027-04-01.